
The Year in Review

TB Alliance Stakeholders Association Annual Meeting

Mel Spigelman

Lille, France

October 24, 2011



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Agenda

- Clinical Development Update - C. Mendel
Discussant - P. Davies
- Status of Preclinical Pipeline - Z. Ma
Discussant – B. Laughon
- Market Access Highlights - E. Gardiner
Discussant – L. Ditiu
- Q&A – Open Discussion



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT


TB Alliance Vision



6 – 30 months



2 – 4 months



10 days

**Success will require
novel multi-drug
combinations**



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Highlight of the Year

It is feasible with presently known tools to shorten and simplify treatment of active TB (drug sensitive and drug resistant) to 2 months of therapy with 3 orally bioavailable drugs



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Sub-Highlights of the Year

- Research & Development
- Market access
- Community engagement



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Research & Development

- Mouse model very predictive
- Novel regimens in the mouse shorten therapy to 2 months
- REMox poised to complete patient accrual
- TBA354 advanced into preclinical development
- 4 discovery projects discontinued
- More effective partnering



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Market Access

- Market Access Advisory Committee constituted
- Significant role of the private sector in drug delivery
- The patient perspective
- Pediatric TB – truly neglected and unmet medical need



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Community Engagement (CE) Initiatives

Small Grants Program:

Supports the development of clinical trial site community engagement strategies and Community Advisory Boards (CABs)

Research Literacy:

Improves community knowledge and understanding of TB drug research through intensive training on key concepts and principles

Cross-Site Engagement and Learning:

Provides opportunities for sites to share information about CE, learn from one another, get new ideas for how best to engage the community, and to build new skills

Monitoring and Evaluation:

Develops new tools to measure the impact of CE on outcomes



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

CE Program Update

- 7 clinical sites in Kenya, S. Africa and Tanzania have active community engagement programs and Community Advisory Boards; 2 new programs initiated in 2011
- collaboration with 4 ACTG site Community Advisory Boards participating in REMox initiated in 2011
- 4 research literacy (RL) trainings
- 3 site CE teams conducted additional RL trainings for local community members and clinic staff
- 2nd CE Forum held in June 2011
- M&E Toolkit to measure CE impact being developed in collaboration with NIAID, AVAC, IAVI, HIV/AIDS Alliance



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Thank you !



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT